61-75 of 366

De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®De Novo mHSPC: Recognizing the Patients Who Need More

ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss

Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC

Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®Winning the Battle Against Side Effects: Adverse Event Management in HSPC

Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®Molecular Profiling in mHSPC: Informing Treatment Selection
- advertisement

ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer

Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®Ongoing Trials in Oral Targeted Strategies in Breast Cancer

SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer

First 5 Minutes®: Empowering Shared Decisions in Lung Cancer Screening
CME/CEFirst 5 Minutes®: Empowering Shared Decisions in Lung Cancer Screening
- advertisement

Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
CME/CEChairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines

Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
CME/CEChairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans


































